Cargando…

Concatenating plasma p-tau to Alzheimer’s disease

This scientific commentary refers to ‘Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum’, by Moscoso et al. (doi:10.1093/brain/awaa399).

Detalles Bibliográficos
Autores principales:	Tijms, Betty M, Teunissen, Charlotte E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Scientific Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880662/ https://www.ncbi.nlm.nih.gov/pubmed/33578422 http://dx.doi.org/10.1093/brain/awaa422

Ejemplares similares

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
por: Biessels, Geert Jan
Publicado: (2022)

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Preclinical Alzheimer’s disease: how to predict who will decline next year?
por: Hanseeuw, Bernard J, et al.
Publicado: (2023)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer’s disease
por: Sadleir, Katherine R., et al.
Publicado: (2023)

The plasma peptides of Alzheimer’s disease
por: Florentinus-Mefailoski, Angelique, et al.
Publicado: (2021)

The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain
por: Goudsmit, Jaap
Publicado: (2016)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials
por: Ferreira, Pamela C.L., et al.
Publicado: (2023)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
por: Prins, Samantha, et al.
Publicado: (2022)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2021)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uftejsblqjoiog9ouuivvk8354